GlaxoSmithKline Plc said it expects sales to grow by around 1% at constant exchange rates this year, despite a first-quarter outturn in which both turnover and operating profit declined. The quarterly performance was affected by one-off developments including the divestment of the group’s non-core over-the-counter medicines.
